| dbo:abstract
|
- HU-308 (also known as onternabez, HU308, PPP-003 and ARDS-003) is a cannabidiol (CBD)-derivative drug that acts as a potent cannabinoid agonist. It is highly selective for the cannabinoid-2 receptor (CB2 receptor) subtype, with a selectivity more than 5,000 times greater for the CB2 receptor than the CB1 receptor. The synthesis and characterization of HU-308 took place in the laboratory of Raphael Mechoulam at the Hebrew University of Jerusalem (the HU in HU-308) in the late 1990s. The pinene dimethoxy-DMH-CBD derivative HU-308 was identified as a potent peripheral CB2-selective agonist in in vitro and animal studies in 1990 and 1999. (en)
- L'HU-308 è un cannabinoide sintetico messo a punto dal gruppo del prof. Raphael Mechoulam dell'Università Ebraica di Gerusalemme. Ha un'attività specifica per il recettore cannabinoide CB2. (it)
|
| dbo:casNumber
| |
| dbo:chEBI
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 5816 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chebi
| |
| dbp:chemspiderid
| |
| dbp:excretion
| |
| dbp:h
| |
| dbp:iupacName
|
- [-2-[2,6-Dimethoxy-4-phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol (en)
|
| dbp:kegg
| |
| dbp:legalCa
| |
| dbp:legalStatus
| |
| dbp:legalUk
| |
| dbp:legalUs
| |
| dbp:metabolism
| |
| dbp:o
| |
| dbp:pubchem
| |
| dbp:smiles
| |
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- CFMRIVODIXTERW-FDFHNCONSA-N (en)
|
| dbp:unii
| |
| dbp:verifiedfields
| |
| dbp:verifiedrevid
| |
| dbp:watchedfields
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- HU-308 (also known as onternabez, HU308, PPP-003 and ARDS-003) is a cannabidiol (CBD)-derivative drug that acts as a potent cannabinoid agonist. It is highly selective for the cannabinoid-2 receptor (CB2 receptor) subtype, with a selectivity more than 5,000 times greater for the CB2 receptor than the CB1 receptor. The synthesis and characterization of HU-308 took place in the laboratory of Raphael Mechoulam at the Hebrew University of Jerusalem (the HU in HU-308) in the late 1990s. The pinene dimethoxy-DMH-CBD derivative HU-308 was identified as a potent peripheral CB2-selective agonist in in vitro and animal studies in 1990 and 1999. (en)
- L'HU-308 è un cannabinoide sintetico messo a punto dal gruppo del prof. Raphael Mechoulam dell'Università Ebraica di Gerusalemme. Ha un'attività specifica per il recettore cannabinoide CB2. (it)
|
| rdfs:label
| |
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
